Delving into the Latest Updates on rDEN3Δ30 (DENV-3)(NIAID) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious Diseases

Active Indication-

Inactive Indication

Dengue

Originator Organization

National Institute of Allergy & Infectious Diseases

Active Organization-

Inactive Organization

National Institute of Allergy & Infectious Diseases

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

Infection with dengue viruses is the leading cause of hospitalization and death in children in many tropical Asian countries, and the development of a dengue vaccine is a top health priority. This study will evaluate the safety and immunogenicity of a live attenuated monovalent dengue virus vaccine (rDEN3Δ30) in healthy adults with no history of previous flavivirus infection.

Start Date-

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

NCT03416036

/ CompletedPhase 1IIT

Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge

The purpose of this study is to evaluate the ability of a single dose of a live attenuated recombinant tetravalent dengue vaccine (TetraVax-DV-TV003, referred to as TV003) to protect against infection with a controlled human infection strain of either DENV-2 (rDEN2Δ30-7169) or DENV-3 (rDEN3Δ30) in adults 18 to 50 years of age with no history of previous flavivirus infection.

Start Date28 Nov 2017

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

100 Clinical Results associated with rDEN3Δ30 (DENV-3)(NIAID)

Login to view more data

100 Translational Medicine associated with rDEN3Δ30 (DENV-3)(NIAID)

Login to view more data

100 Patents (Medical) associated with rDEN3Δ30 (DENV-3)(NIAID)

Login to view more data

100 Deals associated with rDEN3Δ30 (DENV-3)(NIAID)

Login to view more data